Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Langlais · SciRah

Researcher profile · Semantic Scholar

A. Langlais

Share profile

A. Langlais — researcher profile on SciRah

h-index: 20
Works: 103
Citations: 2,381

Most-cited papers

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
F. Barlesi, J. Mazières, J. Merlio, D. Debieuvre +28 more
2016The Lancet923 citations Open access
Semantic Scholar
A Randomized Non‐Comparative Phase II Study of Anti‐Programmed Cell Death‐Ligand 1 Atezolizumab or Chemotherapy as Second‐Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT‐1603 Trial
J. Pujol, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot +18 more
2019Journal of Thoracic Oncology170 citations Open access
Semantic Scholar
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
M. Duruisseaux, B. Besse, J. Cadranel, M. Pérol +17 more
2017OncoTarget154 citations Open access
Semantic Scholar
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
C. Leduc, J. Merlio, B. Besse, H. Blons +16 more
2017Annals of Oncology92 citations Open access
Semantic Scholar
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
M. Wislez, J. Mazières, A. Lavolé, G. Zalcman +16 more
2022Journal for ImmunoTherapy of Cancer85 citations Open access
Semantic Scholar
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
J. Pujol, A. Lavolé, E. Quoix, O. Molinier +48 more
2015Annals of Oncology72 citations Open access
Semantic Scholar
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial
J. Mazières, C. Lafitte, C. Ricordel, L. Greillier +15 more
2022Journal of Clinical Oncology68 citations
Semantic Scholar
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
N. Guibert, F. Barlesi, R. Descourt, H. Léna +16 more
2017Journal of Thoracic Oncology66 citations Open access
Semantic Scholar
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
A. Cortot, C. Audigier-Valette, O. Molinier, S. Le Moulec +18 more
2020European Journal of Cancer64 citations Open access
Semantic Scholar
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
S. Brosseau, C. Danel, A. Scherpereel, J. Mazières +16 more
2019Clinical Lung Cancer60 citations Open access
Semantic Scholar
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.
V. Westeel, P. Foucher, A. Scherpereel, J. Domas +32 more
2022The Lancet Oncology52 citations Open access
Semantic Scholar
1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)
M. Wislez, J. Mazières, A. Lavolé, G. Zalcman +16 more
202052 citations Open access
Semantic Scholar
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
G. Herbreteau, A. Langlais, L. Greillier, C. Audigier-Valette +16 more
2020Journal of Clinical Medicine44 citations Open access
Semantic Scholar
LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)
N. Girard, J. Mazières, J. Otto, H. Léna +16 more
2021Annals of Oncology33 citations Open access
Semantic Scholar
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
P. Tomasini, S. Brosseau, J. Mazières, J. Merlio +16 more
2017European Respiratory Journal28 citations
Semantic Scholar
Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.
A. Cortot, C. Audigier-Valette, O. Molinier, S. Le Moulec +14 more
201628 citations
Semantic Scholar
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
S. Baldacci, B. Besse, V. Avrillon, B. Mennecier +20 more
2022European Journal of Cancer27 citations Open access
Semantic Scholar
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.
A. Lavolé, J. Mazières, S. Schneider, S. Brosseau +10 more
2021Lung Cancer24 citations Open access
Semantic Scholar
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
S. Couraud, F. Barlesi, Clara Fontaine-Deraluelle, D. Debieuvre +17 more
2019European Journal of Cancer24 citations
Semantic Scholar
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O. Molinier, B. Besse, F. Barlesi, C. Audigier-Valette +17 more
2021ESMO Open21 citations Open access
Semantic Scholar
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
E. Maille, S. Brosseau, V. Hanoux, C. Créveuil +16 more
2019British Journal of Cancer20 citations Open access
Semantic Scholar
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) bio
M. Beau-Faller, E. Pencreach, C. Leduc, H. Blons +16 more
2019Lung Cancer19 citations Open access
Semantic Scholar
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.
H. Blons, J. Oudart, J. Merlio, D. Debieuvre +16 more
2020Lung Cancer18 citations Open access
Semantic Scholar
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
A. Ruppert, M. Beau-Faller, D. Debieuvre, L. Ouafik +17 more
2020JTO Clinical and Research Reports17 citations Open access
Semantic Scholar
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
A. Lavolé, L. Greillier, J. Mazières, I. Monnet +11 more
2020European Respiratory Journal13 citations Open access
Semantic Scholar
A randomized non-comparative phase II study of anti-PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial.
J. Pujol, L. Greillier, C. Valette, D. Moro-Sibilot +16 more
2018Annals of Oncology13 citations Open access
Semantic Scholar
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial
G. Levallet, F. Dubois, P. Fouret, M. Antoine +16 more
2016OncoTarget13 citations Open access
Semantic Scholar
972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial
G. Zalcman, A. Flandin, O. Molinier, C. Dayen +16 more
2022Annals of Oncology12 citations Open access
Semantic Scholar
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.
P. Mordant, S. Brosseau, B. Milleron, N. Santelmo +14 more
2022Clinical Lung Cancer11 citations Open access
Semantic Scholar
Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).
D. Moro-Sibilot, C. Audigier-Valette, P. Merle, E. Quoix +11 more
2015Lung Cancer11 citations
Semantic Scholar
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.
E. Gobbini, A. Langlais, P. Missy, S. Chanoine +16 more
2025European Journal of Cancer10 citations Open access
Semantic Scholar
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Jean Baptiste Oudart, S. Garinet, C. Léger, F. Barlesi +10 more
2024Lung Cancer10 citations Open access
Semantic Scholar
Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.
J. Mazières, C. Lafitte, C. Ricordel, L. Greillier +15 more
202110 citations
Semantic Scholar
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
E. Quoix, C. Audigier-Valette, A. Lavolé, O. Molinier +17 more
2020European Journal of Cancer10 citations
Semantic Scholar
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504
J. Cadranel, R. Gervais, P. Merle, D. Moro-Sibilot +16 more
2015European Respiratory Journal9 citations
Semantic Scholar
1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial
M. Wislez, J. Mazières, A. Lavolé, G. Zalcman +16 more
2021Annals of Oncology8 citations Open access
Semantic Scholar
Development and Validation of a Simplified Prognostic Score in SCLC
E. Negre, A. Coffy, A. Langlais, J. Daurès +10 more
2020JTO Clinical and Research Reports7 citations Open access
Semantic Scholar
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
G. Zalcman, A. Madroszyk, C. Dayen, O. Molinier +16 more
2023Journal of Clinical Oncology6 citations
Semantic Scholar
FP09.05 Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study
L. Mezquita, F. Barlesi, G. Ielsch, J. Merlio +17 more
20216 citations Open access
Semantic Scholar
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
M. Wislez, C. Domblides, L. Greillier, J. Mazières +16 more
2021Lung Cancer6 citations Open access
Semantic Scholar
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial
F. Dubois, M. Keller, J. Hoflack, E. Maille +11 more
2019Cancers6 citations Open access
Semantic Scholar
Livestock farming and nitrogen within the economic and social context
A. Langlais, C. Nicourt, M. Bourblanc, C. Gaigné
20146 citations Open access
Semantic Scholar
Nitrogen flows and livestock farming: lessons and perspectives
J. Peyraud, P. Cellier, F. Aarts, F. Béline +21 more
20146 citations
Semantic Scholar
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial
E. Maille, J. Levallet, F. Dubois, M. Antoine +16 more
2022International Journal of Cancer4 citations Open access
Semantic Scholar
1389P IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced non-small cell lung cancer (NSCLC)
A. Lavolé, J. Mazières, S. Schneider, S. Brosseau +10 more
20203 citations Open access
Semantic Scholar
OA11.01 Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study
A. Cortot, C. Valette, O. Molinier, S. Le Moulec +14 more
20173 citations Open access
Semantic Scholar
IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)–associated advanced non-squamous non-small cell lung cancer (NS-NSCLC).
A. Lavolé, P. Tomasini, I. Monnet, L. Kiakouama-Maleka +12 more
20163 citations
Semantic Scholar
Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
C. Leduc, H. Blons, B. Besse, J. Merlio +16 more
20163 citations Open access
Semantic Scholar
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.
T. Walter, J. Mazières, Josiane Otto, Hervé Léna +26 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study.
H. Blons, J. Oudart, J. Merlio, S. Hominal +16 more
2018Annals of Oncology2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Morin×40
Invite
F. Morin — researcher profile on SciRah
V. Westeel×23
Invite
V. Westeel — researcher profile on SciRah
J. Mazières×22
Invite
J. Mazières — researcher profile on SciRah
C. Audigier-Valette×21
Invite
C. Audigier-Valette — researcher profile on SciRah

D. Moro-Sibilot

×21

Invite

D. Moro-Sibilot — researcher profile on SciRah

Invite

F. Barlesi — researcher profile on SciRah

Invite

G. Zalcman — researcher profile on SciRah

J. Cadranel×17

Invite

J. Cadranel — researcher profile on SciRah

Invite

B. Besse — researcher profile on SciRah

O. Molinier×16

Invite

O. Molinier — researcher profile on SciRah

D. Debieuvre×14

Invite

D. Debieuvre — researcher profile on SciRah

Invite

I. Monnet — researcher profile on SciRah